Zengchun Hu | Anti-Tumor Therapy | Best Researcher Award

Published on by China Scientist

Prof. Dr. Zengchun Hu | Anti-Tumor Therapy | Best Researcher Award 

Zengchun Hu is a chief neurosurgeon and doctoral supervisor at The Second Affiliated Hospital of Dalian Medical University, specializing in the surgical and comprehensive treatment of gliomas, malignant brain tumors, and cerebrovascular diseases. A doctoral graduate in neurosurgery from Dalian Medical University, he further trained at Beijing Tian Tan Hospital to refine advanced surgical skills. He has contributed extensively to national research projects, published in leading SCI journals, and authored a neurosurgical textbook. His research explores lipid and sugar metabolism, ferroptosis, and targeted therapies in glioma and lung cancer, aiming to develop innovative treatment strategies that improve patient outcomes.

Prof. Dr. Zengchun Hu | The Second Affiliated Hospital of Dalian Medical University | China

Profile

SCOPUS

Education

  • Zengchun Hu earned his doctoral degree in neurosurgery from Dalian Medical University, establishing a strong foundation in surgical techniques and clinical neurology. He further enhanced his expertise through subspecialization training in neurosurgery at Beijing Tian Tan Hospital, where he refined advanced skills in managing complex neurological conditions. His academic journey combined rigorous research engagement with extensive clinical exposure, preparing him for a career at the forefront of neurosurgical innovation.

Experience

  • Currently serving as a chief neurosurgeon and doctoral supervisor at The Second Affiliated Hospital of Dalian Medical University, Zengchun Hu has built a reputation for his precision and dedication in neurosurgical care. He is highly experienced in performing surgeries for gliomas, malignant brain tumors, and cerebrovascular diseases. His surgical proficiency allows him to independently handle a large number of brain tumor operations annually. In addition to his clinical work, he has contributed to multiple national-level research projects and has authored numerous peer-reviewed articles in high-impact scientific journals.

Awards and Recognition

  • Zengchun Hu’s leadership in neurosurgery and his academic contributions have earned him recognition within both clinical and research communities. As the editor-in-chief of a specialized neurosurgical textbook published by Jilin Science and Technology Press, he has contributed to shaping the educational landscape for upcoming neurosurgeons. His appointment as an editorial board member for the Translational Medicine Electronic Journal and his role as a young editor further reflect his standing as a respected thought leader in his field.

Skills and Expertise

  • Zengchun Hu possesses exceptional skills in brain tumor surgery, cerebrovascular disease management, and advanced neurosurgical techniques. His expertise extends to integrating traditional and modern medical approaches in neurosurgical care. He is adept at leading multidisciplinary teams, mentoring doctoral candidates, and translating cutting-edge research findings into practical therapeutic strategies. His academic and clinical synergy ensures comprehensive patient care while advancing neurosurgical science.

Research Focus 

  • Zengchun Hu’s research is centered on the surgical and comprehensive treatment of gliomas and other malignant tumors. He investigates the mechanisms of lipid and sugar metabolism as well as ferroptosis in the development of gliomas and lung cancer. His studies have highlighted the therapeutic potential of targeting SVIP in glioblastoma progression and have revealed the anti-cancer effects of CPP through Nrf2 degradation and ferroptosis sensitization in non-small cell lung cancer. His work aims to develop novel therapeutic strategies that combine surgery with targeted molecular treatments to improve survival and quality of life for cancer patients.

Publications

  • Periplocin potentiates ferroptotic cell death in non-small cell lung cancer by inducing the degradation of Nrf2
    Authors: Jinhao Wang, Yue Zhu, Jialiang Song, Fengping Yang, Peng Wang, Ziyi Zhang, Yuxuan Li, Minghe Dai, Yinuo Wang, Waleed Yousuf, Jiayu Li, Dian Yang, Shaoxuan Cheng, Shuyan Liu, Zhaoxia Dai, Xun Qiu, Yingqiu Zhang, Zengchun Hu
    Journal: Cancer Cell International

  • Mechanism of microRNA-152-3p-Mediated Regulation of Autophagy and Sensitivity in Paclitaxel-Resistant Ovarian Cancer Cells
    Authors: Di Wu, Yang Zhang, Luna Zhang, Wanying Xia, Bingkun Cai, Feihong Dong, Ke Wu, Lichun Cheng, Mingkun Shao, Hui Ma, Zengchun Hu, Huiyi Lu
    Journal: OncoTargets and Therapy

  • SVIP reduces IGFBP-2 expression and inhibits glioblastoma progression via stabilizing PTEN
    Authors: Zixuan Wang, Xiaolong Qiao, Yinan Chen, Nan Peng, Chaoshi Niu, Yang Wang, Cong Li, Zengchun Hu, Caihua Zhang, Chuandong Cheng
    Journal: Cell Death Discovery

  • Pharmacological inhibition of the ubiquitin-specific protease 8 effectively suppresses glioblastoma cell growth
    Authors: Yu Long, Zengchun Hu, Dian Yang, Fuqiang Wang, Chen’ge Zhao, Yang Zhang, Yingqiu Zhang, Hui Ma, Huiyi Lv
    Journal: Open Life Sciences

  • Tanshinone IIA Microemulsion Protects against Cerebral Ischemia Reperfusion Injury via Regulating H3K18ac and H4K8ac In Vivo and In Vitro
    Authors: Hui Ma, Zeng-Chun Hu, Yu Long, Li-Chun Cheng, Chen-Yang Zhao, Ming-Kun Shao
    Journal: American Journal of Chinese Medicine

Conclusion

  • Through his combined roles as a surgeon, educator, and researcher, Zengchun Hu has established himself as a prominent figure in neurosurgery. His work reflects a dedication to improving surgical outcomes, advancing research in cancer treatment, and mentoring the next generation of neurosurgical specialists. By aligning clinical practice with scientific discovery, he continues to make a significant impact in both patient care and medical research.

Dengke Bao | Tumor biology | Best Researcher Award

Published on by China Scientist

Prof. Dr. Dengke Bao | Tumor biology | Best Researcher Award 

Dengke Bao, Ph.D., is a professor, Ph.D. supervisor, and Deputy Dean at the School of Pharmacy, Henan University. He is a recipient of the Excellent Youth Fund Project of the Henan Natural Science Foundation and the 2022 China Postdoctoral Science Foundation Funding. His research focuses on mitochondria-related mechanisms in tumorigenesis, cancer progression, and immune regulation. He has published 20+ SCI-indexed papers in top journals like Oncogene and Cell Death & Disease and serves as an editorial member for Scientific Reports. His work provides new insights into tumor microenvironment remodeling and drug resistance in cancer therapy.

Prof. Dr. Dengke Bao | Henan University | China

Profile

SCOPUS ID

ORCID ID

🎓Education

  • Dengke Bao holds a Ph.D. and has established himself as a distinguished professor and Ph.D. supervisor. His academic journey has been marked by excellence, leading to his recognition as a Program for Central Plains Youth Top Talent and a recipient of multiple prestigious research grants.

👨‍🏫Experience

  • Currently serving as the Deputy Dean of the School of Pharmacy at Henan University, Dengke Bao has played a pivotal role in advancing molecular diagnostics and therapy. He is also the Deputy Director of the Henan Engineering Research Center for Molecular Diagnosis and Therapy of Esophageal Cancer and the Director of the Laboratory of Biomarkers and Liquid Biopsy in Kaifeng. His work has significantly contributed to understanding mitochondria-related mechanisms in tumorigenesis, cancer progression, and tumor immune regulation.

🏆Awards and Recognitions

  • Dengke Bao has been honored with numerous awards, including the Excellent Youth Fund Project of the Henan Natural Science Foundation and recognition as a Young Core Instructor of Henan. He was also a recipient of the 2022 China Postdoctoral Science Foundation Funding, highlighting his exceptional contributions to the field of oncology research.

💡Skills and Certifications

  • With a deep expertise in tumor biology and the tumor microenvironment, Dengke Bao specializes in investigating mitochondrial damage-associated molecular patterns (DAMPs) and their role in inflammatory responses and cancer therapy resistance. His research combines molecular biology, oncology, and immunology to uncover new therapeutic strategies for hepatocellular carcinoma (HCC) and other malignancies.

🔬 Research Focus

  • Dengke Bao’s research is centered on understanding how mitochondrial damage-associated molecular patterns influence the tumor microenvironment and immune regulation. His groundbreaking study demonstrated that sorafenib treatment in HCC induces the release of mitochondrial DNA into the tumor microenvironment, promoting M2 macrophage polarization through TLR9 activation and enhancing sorafenib resistance. His findings offer a new perspective on targeting mitochondrial DAMPs to reprogram tumor-associated macrophages, providing novel strategies to improve therapeutic efficacy and overcome drug resistance in cancer treatment.

 📚 Publications and Editorial Roles

  • Dengke Bao has authored over 20 SCI-indexed papers as a first or corresponding author in high-impact journals, including Oncogene, Journal of Experimental & Clinical Cancer Research, and Cell Death & Disease. He also serves as an editorial member for Scientific Reports, further solidifying his influence in the field of cancer research.

🌎Conclusion

  • Given his exceptional research contributions, leadership, and impact in oncology, Dengke Bao is a highly suitable nominee for the Research for Best Researcher Award. His work is not only innovative but also holds great promise for improving cancer treatment and patient outcomes, making him a deserving recipient of this prestigious recognition.

📖Publications

  • TEFM facilitates uterine corpus endometrial carcinoma progression by activating ROS-NFκB pathway

    • Authors: J. Lei, Q. Zhu, J. Guo, D. Bao, R. Guo
    • Journal: Journal of Translational Medicine, 2024

  • Tenofovir disoproxil fumarate mediates neuronal injury by inducing neurotoxicity

    • Authors: X. Yang, J. Zhang, Y. Cheng, H. Liu, D. Bao
    • Journal: European Journal of Clinical Microbiology and Infectious Diseases, 2023

  • PRRSV infection activates NLRP3 inflammasome through inducing cytosolic mitochondrial DNA stress

    • Authors: H. Li, X. Yang, Y. Song, B. Wan, D. Bao
    • Journal: Veterinary Microbiology, 2023